Advertisement

Topics

Companies Related to "EGFR PI3K PDK1 pathway regulates signaling hepatocellular carcinoma" [Most Relevant Company Matches] RSS

15:58 EDT 16th August 2018 | BioPortfolio

Here are the most relevant search results for "EGFR PI3K PDK1 pathway regulates signaling hepatocellular carcinoma" found in our extensive corporate database of over 50,000 company records.

Showing "EGFR PI3K PDK1 pathway regulates signaling hepatocellular carcinoma" Companies 1–25 of 273

Extremely Relevant

Semafore Pharmaceuticals

Semafore Pharmaceuticals is a private, clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule signal transduction inhibitors targeting the phosphoinositide-3-kinase (PI3K) pathway for the treatment of cancer and other serious diseases. In addition to SF1126, the Company is developing SF2626, a next-generatio...


Semafore Pharmaceuticals, Inc.

Founded in 2000, Semafore Pharmaceuticals is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule signal transduction inhibitors targeting the phosphoinositide-3-kinase (PI3K) pathway for the treatment of cancer and other serious diseases. The PI3K signaling pathway is vital to several biological process...

Semafore Pharmaceuticals Inc.

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus -- cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN. The co...


Arno Therapeutics, Inc.

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. In addition to AR-67, Arno's lead clinical compound is AR-12, a potentially first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway and induces autophagy and the endoplasmi...

Relevant

Calistoga Pharmaceuticals, Inc.

Calistoga Pharmaceuticals is dedicated to developing targeted therapy to improve the health of patients with cancer and inflammatory diseases. Calistoga Pharmaceuticals has a portfolio of proprietary compounds selectively targeting isoforms of the PI3K pathway. The Company’s most advanced compound, CAL-101, a selective PI3K delta inhibitor, is under c...

Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted can...

Kite Pharma, Inc.

Kite Pharma, Inc. is a privately held development stage biotechnology company engaged in the design and development of cutting-edge immunotherapeutic products to treat different cancer indications. Kite's lead products include antigens associated with a wide variety of tumor types, and are initially being developed for the treatment of renal cell carcinoma...

Pathway Therapeutics, Inc.

Pathway Therapeutics is a privately held pharmaceutical company focused on the discovery and development of best in class, selective inhibitors of PI3K/mTOR for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit. The company was founded in 2008 based on technology from the University of Auckland. The co...

Ironwood Pharmaceuticals , Inc.

IW-1973 and IW-1701 are investigational clinical compounds from Ironwood’s library of pharmacologically distinct soluble guanylate cyclase (sGC) stimulators. The stimulation of sGC is a clinically validated approach with broad therapeutic potential. Found throughout the body, sGC is an enzyme that is activated by the key regulator nitric oxide (NO) to...

Intellikine, Inc.

Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway. Intellikine recently announced the start of a Phase I trial for INK128, a selective TORC1/2 inhibitor for oncology and is advancing INK1197, a PI3K-delta/gamma dual-selective inhibitor for the treatment of inflammatory and respiratory diseas...

Pathway Healthcare, LLC

Pathway Healthcare, LLC, based in Dallas, TX, is a team of specialists committed to helping patients suffering from drug and alcohol addiction and dependency. Pathway’s proprietary MAT Plus™ program combines medication assisted treatment and behavioral counseling in a professional and convenient outpatient setting. Pathway Healthcare provides car...

Phoenix Pharmacologics Inc.,

Phoenix Pharmacologics Inc., with its principal headquarterslocated in, San Diego, California, is a privately-held emerging biopharmaceutical company that specializes in developing drugs to treat cancer and related disorders. Two of its protein drugs are in late stage clinical trials: ADI-PEG 20 for the treatment of hepatocellular carcinoma and metastatic melanoma,and Uricase-PEG 20 for the treatm...

Pathway Genomics

Located in San Diego, California, Pathway Genomics is a privately held, venture-backed company that offers both genetic health and ancestry reports. Using customized and innovative DNA genetic testing technologies, Pathway Genomics conducts Comprehensive Genotyping services to generate personalized reports about an individual’s carrier status, pharmac...

Verastem, Inc. Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR a...

Pathway Genomics Inc.

Located in San Diego, California, Pathway Genomics is a privately held, venture-backed company that offers both genetic health and ancestry reports. Using customized and innovative DNA genetic testing technologies, Pathway Genomics conducts comprehensive genotyping services to generate personalized reports about an individual’s carrier status, pharmac...

Nuvelo, Inc.

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical proce...

BioImage A/S

BioImage A/S uses its expertise in redistributionâ„¢ technologies to discover drug candidates that change the activity of specific signaling pathways without inhibiting the catalytic activity of signaling proteins. Increased or decreased activity of a pathway is achieved by targeting the exquisitely specific interactions by which signaling proteins control cellular information flow. BioImage s...

Pathway Genomics OME

Since its founding in 2008, Pathway Genomics (www.pathway.com) has become known for its dedication to innovation – making it a leader in the commercial healthcare industry. Focusing on providing users with the most validated and personalized healthcare information delivered to any device, the company’s program with IBM data is the first of its kind ...

Pathway Genomics Corporation

Located in San Diego, California, Pathway Genomics owns and operates an onsite federally CLIA (Clinical Laboratory Improvement Amendments) certified and California state-licensed laboratory that offers genetic testing services. Using customized and scientifically validated genetic testing technologies within a controlled and secure environment, Pathway Gen...

Complexa, Inc.

Complexa, Inc. is a platform biopharmaceutical company researching and developing endogenous human cell signaling technologies targeting an array of prevalent inflammatory and metabolic diseases. The company’s proprietary technology involves the synthesis and therapeutic applications of endogenous nitro-fatty acids (NFAs) and additional structure/func...

Annexon Bioscience

Annexon is pioneering the development of classical complement pathway inhibitors for the treatment of neurodegenerative and autoimmune diseases. While the role of the pathway in autoimmunity has been known for some time, the Company’s breakthrough research has unveiled that the pathway is activated as the aging brain encounters stress or disease to co...

Upstate Biotechnology Incorporated

Upstate Biotechnology Inc. provides the life science community with the highest quality, innovative bioreagents and the critical information needed to use them successfully in cell biology experiments. Besides carrrying antibodies, enzymes, growth factors and cytokines to every major signaling pathway, Upstate Biotechnology also specializes in phospho-specific antibodies and high throughput screen...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver....

Intracel

Intracel is a leading commercial-stage biotechnology company focused on the development of immune therapy to treat cancer. The company’s pipeline includes product development programs in active immunotherapy and fully human monoclonal antibodies. Intracel has completed clinical studies in Colon, Renal and Ovarian carcinoma, as well as Melanoma. Business StrategyRestructured company to focus o...

CellZome AG

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. Cellzome's emerging pipeline includes a small molecule Histamine H4 receptor antagonist, ...


More From BioPortfolio on "EGFR PI3K PDK1 pathway regulates signaling hepatocellular carcinoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks